MedTrace Logo

Influence of Vasopressors on Anti-Xa Activity in Critically Ill Patients

NCT06055907 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-09-28

No results posted yet for this study

Summary

Critically ill patients require antithrombotic prophylaxis. At the same time, majority of them is receiving various vasopressors. The aim of the study is to determine whether there is a difference in anti-Xa activity, which is a marker of anti thrombotic activity of low molecular weight heparins, between the patients receiving norepinephrine with argipressin, compared to those receiving norepinephrine alone.

Conditions

Interventions

DIAGNOSTIC_TEST

Serum anti-Xa activity

4 hours after third dose of dalteparin, serum anti-Xa activity is measured

Sponsors & Collaborators

  • Medical University of Gdansk

    lead OTHER

Principal Investigators

  • Radosław Owczuk, MD., PhD., Prof. · Medical University of Gdansk

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-15
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06055907 on ClinicalTrials.gov